Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CNM-ZnAg · 1 trial · 1 indication
Time to substantial alleviation of COVID-19 symptoms up to 28-days, over a continuous period ≥ 48 hours (confirmed symptom resolution), defined as PGI-Severity of 'Normal' in Participants whose Baseline PGI-Severity value was 'Mild'; or, a PGI-Severity of 'Normal' or 'Mild' in participants whose Baseline PGI-Severity value was 'Moderate' or 'Severe'.
| Arm | Type | Description |
|---|---|---|
| Active treatment with 60 ml low-dose ZnAg | EXPERIMENTAL | (Zn 6 ug/ml and Ag 10 ug/ml; equivalent to 0.6 mg Ag, 0.36 mg Zn), po q12 hours |
| Active treatment with 60 ml high-dose ZnAg | EXPERIMENTAL | (Zn 12 ug/ml and Ag 20 ug/ml; equivalent to 1.2 mg Ag, 0.72 mg Zn), po q12 hours; |
| 60 ml matching placebo | PLACEBO_COMPARATOR | 60 ml matching placebo, po q12 hours |
| Name | Type | Description |
|---|---|---|
| CNM-ZnAg | DRUG | ZnAg liquid solution |
| Placebo | DRUG | Water |
Inclusion Criteria: 1. Adults, aged 40 - 90 years (inclusive) 2. Acute onset (within 96 hours of the Baseline visit) of two or more COVID-19 symptoms self-rated as moderate-to-severe, including fever, myalgia, fatigue, chest tightness, chills, cough, diarrhea, gastrointestinal distress, headache, s...
CNM-ZnAg is an investigational small molecule being studied for the treatment of symptomatic COVID-19. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
CNM-ZnAg is being developed by Clene Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CLNN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in COVID-19 patients.
CNM-ZnAg is in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval. A Phase 2 trial has been completed to assess its effects in symptomatic COVID-19 participants.
CNM-ZnAg has one completed Phase 2 clinical trial, identified as NCT04610138, titled 'Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants.' This randomized, double-blind, placebo-controlled trial enrolled 296 participants aged 40 years and older in Brazil.
CNM-ZnAg is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for COVID-19. The drug has completed a clinical trial, but it remains unapproved and is still being evaluated for safety and efficacy.